Biogen's Target Hike Meets a Known Q3 R&D Charge

Biogen rose about 5% after Bank of America raised its price target to $244 from $219 while keeping a Neutral rating. TD Cowen maintained a Buy rating and a $250 target. The move put the shares above both targets, which makes the October 28 earnings report more important than the upgrades themselves.

The argument for a higher valuation starts with the company's newer medicines. In the second quarter, total revenue increased 3% to $2.74 billion. Biogen's growth portfolio produced about $1.06 billion of revenue, up 24% from a year earlier, helping offset declines in older multiple-sclerosis and biosimilar products. Management raised its 2026 revenue expectation to mid-single-digit growth.

Reported earnings need careful interpretation. Biogen's second-quarter GAAP diluted earnings were $0.66 a share, while non-GAAP diluted earnings were $3.60. The gap reflected acquisition and research-related costs, including $164 million of acquired in-process research and development, upfront and milestone expense.

Another large charge was already expected for the third quarter. In July, Biogen said it anticipated $290 million to $320 million of acquired research and milestone expense, with an estimated impact of $1.75 to $1.95 a share. A later preliminary update narrowed the expected per-share effect to about $1.65. These costs are tied to transactions and milestones rather than the operating performance of products already on the market, but they still reduce both GAAP and the company's stated non-GAAP earnings.

That is why a quiet quarter on revenue can still produce a noisy earnings comparison. Investors should separate progress in the commercial portfolio from the accounting impact of business-development spending, while also asking whether those investments can create enough future sales to justify the current expense.

Biogen's July guidance called for 2026 non-GAAP diluted earnings of $12 to $13 a share after incorporating acquired research charges and expected dilution from the Apellis acquisition. The company also expected second-half research and selling expenses of $2.65 billion to $2.70 billion, reflecting integration and launch spending.

The October 28 report has three clear tests. Growth products must continue to offset the legacy portfolio, management must explain any change in the research-charge estimate, and the full-year outlook must hold after acquisition integration. The analyst target increases are supportive, but with the stock already above those targets, the next durable catalyst must come from operating evidence rather than another valuation reset.